AmerisourceBergen has been selected by Deciphera to support Qinlock (ripretinib).
The product is an orally administered kinase switch control inhibitor approved for the treatment of adult patients with advanced gastrointestinal stromal tumor, or GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.
In the United States, there are an estimated 4,000 to 6,000 cases of GIST, a rare form of cancer, diagnosed annually.The gastrointestinal cancer is characterized by disease-related symptoms, including vague abdominal pain, early feelings of fullness, vomiting and fatigue due to anemia.
“At AmerisourceBergen, we believe we have a responsibility to help create healthier futures – for patients and our partners. The opportunity to work with Deciphera and support the launch of Qinlock is the perfect example of how our integrated services work together to fulfill that purpose,” said Jenny Fallone, director, AmerisourceBergen Global Branded & Specialty Sourcing. “We are proud that Deciphera selected us to help ensure patients affected by this rare disease – who have exhausted other treatments – have a new therapeutic option. By working together, we can accelerate product performance but, most importantly, increase patient access to this innovative treatment.”